thread-index: Adzzg8wyNu0d853cRJaZPneKIbgkzA== Thread-Topic: =?utf-8?Q?Dr._Marek_Jan_=C5=81os?= From: "http://gsia.sums.ac.ir/" Subject: =?utf-8?Q?Dr._Marek_Jan_=C5=81os?= Organization: Targan Management Systems, http://www.targan.ir MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_006E_01DCF349.1FDD9610" Content-Location: https://gsia.sums.ac.ir/en/ps/menu/18825 Content-Class: urn:content-classes:message Importance: normal Priority: normal X-MimeOLE: Produced By Microsoft MimeOLE This is a multi-part message in MIME format. ------=_NextPart_000_006E_01DCF349.1FDD9610 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable =20 =20 Shiraz University of Medical Sciences - SUMS=20 Code : 18825 Publish Date : Monday, June 15, 2020 Visit : 2187=20 Dr. Marek Jan =C5=81os=20 Dr. Marek Jan =C5=81os=20 =20 Dr. Marek Jan =C5=81os Professor of Cell Biology and Regenerative Pharmacology Department of Pathology, Biotechnology Center Medical Faculty Silesian University of Technology Pomeranian Medical University =20 E-mail Address: mjelos@gmail.com Phone: +48 32237 2908 Address: 8 Krzywousty St., 44-100 Gliwice / 151 Unii Lubelskiej St., 71-344 Szczecin, Poland CV =20 =20 Biography Marek =C5=81os studied medicine at Jagiellonian Univ., Krakow, Poland. = He obtained his doctoral degree from Heidelberg University in 1995, and Habilitation in Molecular Medicine (an academic teaching license) from the University of Muenster in 2002. At the moment he holds several academic positions; he is a professor at Biotechnology Center at the Silesian University of Technology, simultaneously holds a visiting professorship position at the Pomeranian Medical University in Szczecin, Poland, is an honorary visiting professor at Jinan University, Guangzhou (Canton), China, and is a senior scientific adviser at Linkocare Life Sciences AB, Link=C3=B6ping, Sweden, whose = core business is the production of artificial corneas. Dr. =C5=81os has (co-)authored over 170 scientific papers, some of which have been highly-cited, and has also edited several books. His H-index is 56 and his papers are cited over 90 times on average (his total number of citations is approximately 16 000 to date). Moreover, he has been serving as member of a number of editorial boards of scientific journals, as well as on various grant review committees in Europe and in Canada. Dr. =C5=81os pursues various research projects in the fields = of regenerative medicine, biomaterials, biotechnology, oncology, and targeted cancer therapies. His most important scientific achievements were the description of involvement of caspase family of proteases in CD95 (APO-1/Fas) mediated apoptosis, (Los et al., 1995; Nature 375: 81-83), and the discovery of the role of kinase Akt both in the regulation of cell survival and cell death of cancer cells (Maddika et al., 2008, J. Cell Sci.; Maddika et al., 2009, Mol. Cell. Biol.). His research program makes practical and effective use of modern methods like DNA-, protein- and tissue arrays, real-time PCR, proteomics, and animal models. It assimilates technologies from different disciplines like tumor biology, biochemistry, virology, pharmacology, and nanotechnology. To secure effectiveness and competitiveness of scientific work, Dr. =C5=81os is engaged in several local, national, and international collaborations both with industry and the academia. His research interest encompasses medical biotechnology, virology, cell death execution pathways, as well as cancer stem cell biology and the pathophysiology of epigenetic reprogramming (iPS-cells), and transdifferentiation. =20 Research Priorities: * Stem cell biology * Cancer biology * Tissue engineering * Regenerative pharmacology * Advanced biomaterials Previous Academic Collaborations with SUMS: Collaborations with Prof. Saeid Ghavami and Prof. Pooneh Mokarram =20 Number and Duration of Previous Visits to SUMS: 3 times (one-day visits) =20 ------=_NextPart_000_006E_01DCF349.1FDD9610 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: 8bit Shiraz University of Medical Sciences - SUMS
Shiraz University of Medical Sciences - SUMS
Code : 18825      Publish Date : Monday, June 15, 2020 Visit : 2187

Dr. Marek Jan Łos

Dr. Marek Jan Łos

 

Dr. Marek Jan Łos

Professor of Cell Biology and Regenerative Pharmacology

Department of Pathology, Biotechnology Center

Medical Faculty

Silesian University of Technology

Pomeranian Medical University

 

E-mail Address:  mjelos@gmail.com

Phone: +48 32237 2908

Address: 8 Krzywousty St., 44-100 Gliwice / 151 Unii Lubelskiej St., 71-344 Szczecin, Poland

CV

    

 

Biography

Marek Łos studied medicine at Jagiellonian Univ., Krakow, Poland. He obtained his doctoral degree from Heidelberg University  in 1995, and Habilitation in Molecular Medicine (an academic teaching license) from the University of Muenster in 2002. At the moment he holds several academic positions; he is a professor at Biotechnology Center at the Silesian University of Technology, simultaneously holds a visiting professorship position at the Pomeranian Medical University in Szczecin, Poland, is an honorary visiting professor at Jinan University, Guangzhou (Canton), China, and is a senior scientific adviser at Linkocare Life Sciences AB, Linköping, Sweden, whose core business is the production of artificial corneas. Dr. Łos has (co-)authored over 170 scientific papers, some of which have been highly-cited, and has also edited several books. His H-index is 56 and his papers are cited over 90 times on average (his total number of citations is approximately 16 000 to date). Moreover, he has been serving as member of a number of editorial boards of scientific journals, as well as on various grant review committees in  Europe and in Canada. Dr. Łos pursues various research projects  in the fields of regenerative medicine, biomaterials, biotechnology, oncology, and targeted cancer therapies. His most important scientific achievements were the description of involvement of caspase family of proteases in CD95 (APO-1/Fas) mediated apoptosis, (Los et al., 1995; Nature 375: 81-83), and the discovery of the role of kinase Akt both in the regulation of cell survival and cell death of cancer cells (Maddika et al., 2008, J. Cell Sci.; Maddika et al., 2009, Mol. Cell. Biol.). His research program makes practical and effective use of modern methods like DNA-, protein- and tissue arrays, real-time PCR, proteomics, and animal models. It assimilates technologies from different disciplines like tumor biology, biochemistry, virology, pharmacology, and nanotechnology. To secure effectiveness and competitiveness of scientific work, Dr. Łos is engaged in several local, national, and international collaborations both with industry and the academia. His research interest encompasses medical biotechnology, virology, cell death execution pathways, as well as cancer stem cell biology and the pathophysiology of epigenetic reprogramming (iPS-cells), and transdifferentiation.

 

Research Priorities:

  • Stem cell biology
  • Cancer biology
  • Tissue engineering
  • Regenerative pharmacology
  • Advanced biomaterials

Previous Academic Collaborations with SUMS:

Collaborations with Prof. Saeid Ghavami and Prof. Pooneh Mokarram

 

Number and Duration of Previous Visits to SUMS:

3 times (one-day visits)

 


------=_NextPart_000_006E_01DCF349.1FDD9610--